R01
R01 funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
RFA-DA-26-034: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on the Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic Opioids
NIH Trans-NIH RFA supports basic and applied research on acute exposure effects and delayed effects of ultra-potent synthetic opioids, with recurring R01 due dates in 2026 and 2027.
RFA-DA-26-055: Accelerating the Pace of Substance Use Research Using Existing Data (R01)
NIH’s NIDA RFA-DA-26-055 supports R01 projects that use existing social, behavioral, administrative, and neuroimaging datasets to advance prevention, treatment, and service-delivery research on substance use, HIV, and related outcomes, without collecting primary data.
RFA-DA-27-004: BRAIN Initiative Theories, Models and Methods (R01, No Clinical Trials)
A 2026/2027 NIH BRAIN Initiative NOFO that funds computational, statistical, and data science tool development for analyzing complex multi-scale neural data with up to 15 awards per year from a $6M annual set-aside.
RFA-DC-25-005: In Vivo High-Resolution Imaging for Inner Ear Visualization (R01, Clinical Trial Optional)
This NIH NIDCD RFA funds projects that develop higher-resolution structural or functional imaging for the living human inner ear, with up to $500,000 direct costs per year and FY 2026/2027 allocations.
RFA-DK-26-315: Advancing Research on Digital Health Technology for Type 2 Diabetes (R01)
NIH RFA-DK-26-315 is a clinical-trial R01 opportunity for U.S. institutions to test digital health approaches to improve type 2 diabetes management, with submission cycles in 2026 and 2027 and a strict non-responsiveness rule against tool-building and T1D-only projects.
RFA-FD-25-020: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
FDA’s Office of Orphan Products Development supports clinical trials for rare disease products through OOPD RFA-FD-25-020, including recurring 2026 and 2027 due dates with up to $650,000 annually in base project support.
RFA-HG-25-009: Supporting Talented Early Career Researchers in Genomics (R01)
NIH/NHGRI reissues an R01-style NOFO for highly promising Early Stage Investigators (ESIs) building independent genomics programs, with a maximum direct-cost budget of $400,000 per year and up to a five-year project term.
RFA-MH-26-170: BRAIN Initiative - Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01)
NIH BRAIN Initiative reissue NOFO for R01 projects that develop and validate high-impact tools for precise, cell- and circuit-specific neuroscience research without clinical trials.
RFA-MH-27-135: Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (R01 Clinical Trials Required)
NIH/NIMH is seeking R01 research grants focused on rigorous clinical trials and trial methods for rapid-acting psychotropic interventional drug development, with a FY2027 budget totaling about $5.5M.
RFA-MH-27-180: Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (R01 Clinical Trial Optional)
NIH NIMH is seeking R01 projects that adapt, optimize, and scale evidence-based interventions for adults 50+ living with serious mental illness, with initial submission opening in Sept 2026 and due Oct 15, 2026.